16754-80-6

Basic information

• Product Name: 6-Chloro-7-deazapurine-b-D-riboside
• Synonyms: 4-Chloro-7-(D-ribofuranosyl)pyrrolo[2,3-d]pyrimidine;6-Chloro-7-deazapurine-b-D-riboside;6-Chloro-9-(D-ribofuranosyl)-7-deazapurine;6-Deamino-6-chlorotubercidin;NSC 101161;6-Chloro-7-deaza-9-(b-D-ribofuranosyl)purine;6-CHLORO-7-DEAZAPURINE-SS-D-RIBOSIDE;6-Chloro-7-deaza-9-(β-D-ribofuranosyl)purine
• CAS NO: 16754-80-6
• Molecular Formula: C₁₁H₁₂ClN₃O₄
• Molecular Weight: 285.686
• Product Categories: Bases & Related Reagents;Intermediates;Nucleotides;Carbohydrates & Derivatives
• Mol File: 16754-80-6.mol
• Article Data: 11

Chemical Properties

• Melting Point: 160-162°C
• Boiling Point: 591.4°Cat760mmHg
• Flash Point: 311.5°C
• Appearance: /
• Density: 1.87g/cm³
• Vapor Pressure: 7.8E-15mmHg at 25°C
• Refractive Index: 1.786
• Storage Temp.: -20°C Freezer
• Solubility: DMSO (Slightly), Methanol (Slightly)
• PKA: 12.39±0.70(Predicted)
• CAS DataBase Reference: 6-Chloro-7-deazapurine-b-D-riboside(CAS DataBase Reference)
• NIST Chemistry Reference: 6-Chloro-7-deazapurine-b-D-riboside(16754-80-6)
• EPA Substance Registry System: 6-Chloro-7-deazapurine-b-D-riboside(16754-80-6)

Safety Data

• Hazardous Substances Data: 16754-80-6(Hazardous Substances Data)

Usage

Chemical Properties

Colourless Crystalline Solid

Uses

Different sources of media describe the Uses of 16754-80-6 differently. You can refer to the following data:
1. An adenosine kinase inhibitor
2. An adenosine kinase inhibitor.

InChI:InChI=1/C11H12ClN3O4/c12-9-5-1-2-15(10(5)14-4-13-9)11-8(18)7(17)6(3-16)19-11/h1-2,4,6-8,11,16-18H,3H2

Upstream product

• 41028-66-4 1,5-anhydroribitol 
• 55726-00-6 (3R,4S,5R)-5-((trityloxy)methyl)tetrahydrofuran-2,3,4-triol 
• 3680-69-1 4-chloro-1H-pyrrolo[2,3-d]pyrimidine 
• 1615680-91-5 6-chloro-5-((trimethylsilyl)ethynyl)pyrimidin-4-amine 
• 217309-46-1 5-(tert-butyldimethylsilyloxy)-2,3-isopropylidenedioxy-D-ribofuranose 
• 29914-75-8 (2R,3R,4R,5R)-2-((benzoyloxy)methyl)-5-(4-chloro-7H-pyrrolo[2,3-d]pyrimidin-7-yl)tetrahydrofuran-3,4-diyl dibenzoate 
• 1039752-77-6 4-chloro-7-[5-O-[(1,1-dimethylethyl)dimethysilyl]-2,3-O-(1-methylethylidene)-D-ribofuranosyl]-7H-pyrrolo[2,3-d]pyrimidine 
• 75921-20-9 5-O-<(1,1-dimethylethyl)dimethylsilyl>-2,3-O-(1-methylethylidene)-β-D-ribofuranose 
• 102690-94-8 2,3-O-isopropylidene-5-O-(tert-butyldimethylsilyl)-α-D-ribofuranosyl chloride 
• 115479-39-5 4-chloro-7-<5-O-<(1,1-dimethylethyl)dimethylsilyl>-2,3-O-(1-methylethylidene)-β-D-ribofuranosyl>-7H-pyrrolo<2,3-d>pyrimidine 

Downstream Products

• 1039752-83-4 4-[(2-fluorobenzyl)thio]-7-(β-D-ribofuranosyl)-7H-pyrrolo[2,3-d]pyrimidine 
• 1039752-85-6 4-[(2-bromobenzyl)thio]-7-(β-D-ribofuranosyl)-7H-pyrrolo[2,3-d]pyrimidine 
• 1039752-84-5 4-[(2-chlorobenzyl)thio]-7-(β-D-ribofuranosyl)-7H-pyrrolo[2,3-d]pyrimidine 
• 1039752-91-4 4-[(3-methylbenzyl)thio]-7-(β-D-ribofuranosyl)-7H-pyrrolo[2,3-d]pyrimidine 
• 1039752-92-5 4-[(4-fluorobenzyl)thio]-7-(β-D-ribofuranosyl)-7H-pyrrolo[2,3-d]pyrimidine 
• 1039752-94-7 4-[(4-bromobenzyl)thio]-7-(β-D-ribofuranosyl)-7H-pyrrolo[2,3-d]pyrimidine 
• 1039753-01-9 4-[(4-tert-butylbenzyl)thio]-7-(β-D-ribofuranosyl)-7H-pyrrolo[2,3-d]pyrimidine 
• 1039752-99-2 4-[(4-methylbenzyl)thio]-7-(β-D-ribofuranosyl)-7H-pyrrolo[2,3-d]pyrimidine 
• 1039752-86-7 4-[(2-methylbenzyl)thio]-7-(β-D-ribofuranosyl)-7H-pyrrolo[2,3-d]pyrimidine 
• 1039752-89-0 4-[(3-trifluoromethylbenzyl)thio]-7-(β-D-ribofuranosyl)-7H-pyrrolo[2,3-d]pyrimidine 
• 1039752-88-9 4-[(3-nitrobenzyl)thio]-7-(β-D-ribofuranosyl)-7H-pyrrolo[2,3-d]pyrimidine 
• 1039752-97-0 4-[(4-cyanobenzyl)thio]-7-(β-D-ribofuranosyl)-7H-pyrrolo[2,3-d]pyrimidine 
• 1039753-07-5 4-[(3,4-dichlorobenzyl)thio]-7-(β-D-ribofuranosyl)-7H-pyrrolo[2,3-d]pyrimidine 
• 1039753-04-2 4-[(4-methoxybenzyl)thio]-7-(β-D-ribofuranosyl)-7H-pyrrolo[2,3-d]pyrimidine 

Relevant articles and documents

HETEROCYCLIC COMPOUNDS AS PRMT5 INHIBITORS

The present disclosure describes novel heterocyclic PRMT5 inhibitors and methods for preparing them. The pharmaceutical compositions comprising such PRMT5 inhibitors and methods of using them for treating cancer, infectious diseases, and other PRMT5 associated disorders are also described.

ADENOSINE ANALOG AND ITS USE IN REGULATING THE CIRCADIAN CLOCK

Provided are a kind of nucleoside analogue compounds, and compositions comprising these compounds and pentostatin, their use for modulating circadian rhythm, preferably, for shifting circadian phase, and methods for modulating circadian rhythm, preferably, for shifting circadian phase via these compounds or the compositions.

Synthesis of Nucleosides through Direct Glycosylation of Nucleobases with 5-O-Monoprotected or 5-Modified Ribose: Improved Protocol, Scope, and Mechanism

Simplifying access to synthetic nucleosides is of interest due to their widespread use as biochemical or anticancer and antiviral agents. Herein, a direct stereoselective method to access an expansive range of both natural and synthetic nucleosides up to a gram scale, through direct glycosylation of nucleobases with 5-O-tritylribose and other C5-modified ribose derivatives, is discussed in detail. The reaction proceeds through nucleophilic epoxide ring opening of an in situ formed 1,2-anhydrosugar (termed “anhydrose”) under modified Mitsunobu reaction conditions. The scope of the reaction in the synthesis of diverse nucleosides and other 1-substituted riboside derivatives is described. In addition, a mechanistic insight into the formation of this key glycosyl donor intermediate is provided.